Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
Healthcare
$6.23 +3.63%
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
52W Low $3.79High $8.87
Volume 1.13M
Average 1.39M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$179.21M
FY 2025 · Annual
Net Income
-$174.32M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.62M | 8.09M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.58M | 2.46M | 1.64M |
| Gross Profit | 13.62M | 8.09M | (2.58M) | (2.46M) | (1.64M) |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 58.74M | 78.42M | 76.56M | 96.43M | 140.33M |
| Selling, General & Admin | 27.14M | 28.95M | 27.75M | 33.3M | 38.88M |
| Operating Expenses | 85.87M | 114.55M | 101.73M | 127.27M | 177.57M |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M |
| EBITDA | (69.22M) | (96.87M) | (93.43M) | (121.9M) | (172.69M) |
| EBITDA Margin | -508.3% | -1196.8% | — | — | — |
| Operating Income | (72.25M) | (106.45M) | (104.32M) | (129.73M) | (179.21M) |
| Operating Margin | -530.5% | -1315.2% | — | — | — |
| Interest Income | 64K | 2.62M | 7.14M | 9.47M | 9.9M |
| Interest Expense | 0 | 0 | 0 | 340K | 0 |
| Other Income / Expenses | 66K | 20.47M | 8.3M | 5.03M | 4.88M |
| Income Before Tax | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Pre-Tax Margin | -530.0% | -1062.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Net Margin | -530.0% | -1062.3% | — | — | — |
| EPS (Basic) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| EPS (Diluted) | (10.14) | (10.10) | (4.83) | (3.06) | (1.99) |
| 7.12M | 8.51M | 19.88M | 40.82M | 87.5M | |
| 7.12M | 8.51M | 19.88M | 40.82M | 87.5M |
SLDB Earnings Waterfall · TTM
NASDAQ:SLDB · Revenue to Net Income
Key Ratios
EPS$-1.95
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$191.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.95, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 26, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 20, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 |
How much revenue does SLDB generate?
Solid Biosciences Inc. (SLDB) reported $0.00 of revenue in fiscal 2025.
Is SLDB profitable?
Solid Biosciences Inc. (SLDB) reported -$174.32M of net income.
Continue the stock analysis
Jump to another research area for this company.